News Sangamo and new gene therapy partner Pfizer lifted by FDA fa... Sangamo Therapeutics has been granted a fast track designation from the FDA for SB-525, its gene therapy candidate for haemophilia A.
News Ionis hit by safety concerns, rivals Alnylam benefit Biotech insists drug for rare inherited disorder is still approvable.
News Drama as Roche's Tecentriq fails in key bladder cancer trial Roche has been shocked by the late-stage trial failure of its immunotherapy Tecentriq in bladder cancer, a setback which could cost it billions if the drug loses its licence.
Events Partner Content 4th Clinical Regulatory Medical Writing Forum The premier medical writing event dedicated to addressi
News Waiting on NICE decision, Pfizer provides breast cancer drug... NICE rejected Ibrance in initial decision in February.
News Pfizer chief suggests no BMS bid - for now Ian Read won't quash rumours that his company Pfizer could swoop for vulnerable Bristol-Myers Squibb - but says it won't make any major acquisitions
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.